Author: OurCrowd

[EquipmentShare in BusinessWire] EquipmentShare closes $2.75 billion senior secured asset-based revolving credit facility with Wells Fargo

Dec 3, 2025 |

COLUMBIA, Mo.–(BUSINESS WIRE)–EquipmentShare, a leader in connected jobsite technology and one of the largest equipment rental providers in the United States, announced today that it closed an $2.75 billion asset-based senior secured credit facility (the “Facility”). Wells Fargo serves as administrative agent and lead lender for the Facility. Read...

Read More

[Anthropic in Anthropic] Snowflake and Anthropic announce $200 million partnership to bring agentic AI to global enterprises

Dec 3, 2025 |

Today, we announce a significant expansion of our strategic partnership with Snowflake. The multi-year, $200 million agreement will not only make Anthropic’s Claude models available in the Snowflake platform to more than 12,600 global customers across Amazon Bedrock, Google Cloud Vertex AI, and Microsoft Azure, but also establishes a joint go-to-market (GTM) initiative focused on deploying AI agents across the world’s largest enterprises. Read...

Read More

[Blackshark.Ai in Lockheed Martin] Lockheed Martin, Blackshark.ai, debut next-gen image generator powered by unreal engine

Dec 2, 2025 |

ORLANDO, Fla., Dec. 2, 2025 – Today, Lockheed Martin [NYSE: LMT], with Blackshark.ai, unveiled Prepar3D® Fuse, a next‑generation simulation solution to prepare today’s soldier for any mission. Built on a custom version of Unreal Engine 5, Prepar3D® Fuse blends Lockheed Martin’s simulation legacy with commercially available cutting‑edge graphics and AI‑generated terrain and sensor‑modeling, giving warfighters, engineers and instructors a single environment for everything from initial flight training to joint, multi-domain exercises. Read more...

Read More

[Alpha Tau in Alpha Tau] Alpha Tau receives FDA Approval to initiate a trial for patients with locally recurrent prostate cancer

Dec 2, 2025 |

JERUSALEM, December 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with locally recurrent prostate cancer using the Company’s Alpha DaRT technology. Read...

Read More